Cybin Inc. (CYBN.NE)
Cybin Inc. operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Toronto, ON, CA. The stock last traded at $15.52, up 10.07% on the session, giving a market capitalisation of $375.7M. Its beta of -0.95 implies it has historically moved less than the broad market.
Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.
Cybin Inc. is most often compared with the following Healthcare names: